This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.
Will Healthy Y/Y Revenue Growth Boost Keysight's Q2 Earnings?
by Zacks Equity Research
KEYS is expected to report year-over-year revenue growth in the second quarter of fiscal 2025, driven by healthy demand across both segments.
Doximity Q4 Earnings Likely to Reflect Strong Product Momentum
by Zacks Equity Research
Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth.
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86%
by Zacks Equity Research
The mean of analysts' price targets for Altimmune (ALT) points to a 285.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Altimmune Stock Up More Than 25% in a Month: Here's Why
by Zacks Equity Research
ALT's recent progress related to the development of the lead product candidate, pemvidutide, for treating obesity and MASH is aiding the stock.
Brookdale Senior (BKD) Q2 Occupancy Jumps, Growth Trend Persists
by Zacks Equity Research
Brookdale Senior's (BKD) weighted average occupancy for June rises 140 bps year over year.
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
by Zacks Equity Research
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
by Sundeep Ganoria
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Altimmune (ALT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Altimmune (ALT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Altimmune's (ALT) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the development of its lead pipeline candidate, pemvidutide.
Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study
by Zacks Equity Research
Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.
Altimmune (ALT) Rises 7% on Completing Dosing in Obesity Study
by Zacks Equity Research
Altimmune (ALT) completes the dosing of all patients in the mid-stage obesity study of pemvidutide. The company remains on track to announce top-line results in fourth-quarter 2023. The stock rises 7%.
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval
by Zacks Equity Research
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
Altimmune (ALT) Stock Down Despite Positive Obesity Study Data
by Zacks Equity Research
Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate.
Zoetis' (ZTS) Q4 Earnings in Line With Estimates, Revenues Beat
by Zacks Equity Research
Zoetis' (ZTS) fourth-quarter 2022 earnings per share was at par with the Zacks Consensus Estimate, while revenues beat the same. The company provides its financial guidance for 2023.
Teladoc (TDOC) to Reduce Operating Costs, Shares Fall 6.6%
by Zacks Equity Research
Teladoc (TDOC) is likely to book a $17-million charge in 2023, of which, around $10 million will come from staff reduction moves.
Why You Should Keep Acadia Healthcare (ACHC) in Your Portfolio
by Zacks Equity Research
The constant growth in the senior population is expected to be beneficial for companies like Acadia Healthcare (ACHC) as demand for hospital services rises.
Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
Altimmune, Inc. (ALT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 2.04% and 99.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Altimmune's (ALT) Data From NASH Study Fail to Impress Investors
by Zacks Equity Research
Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.
Altimmune, Inc. (ALT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 6.67% and 99.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Altimmune, Inc. (ALT) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Altimmune, Inc. (ALT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Altimmune (ALT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Altimmune, Inc. (ALT) and argenex (ARGX) have performed compared to their sector so far this year.
Molina Healthcare (MOH) to Buy My Choice Wisconsin for $150M
by Zacks Equity Research
Molina Healthcare (MOH) expects the buyout to complement its existing Medicaid business in Wisconsin.
Encompass Health (EHC) to Build New Rehab Unit in Missouri
by Zacks Equity Research
Encompass Health (EHC) and BJC HealthCare's new rehabilitation hospital is expected to come online in 2024.